NCT01256632View on ClinicalTrials.gov

Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Choroidal Neovascularization
Interventions
DRUG

Ranibizumab

All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.

Trial Locations (1)

48073

Vision Research Foundation, Royal Oak

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Vision Research Foundation

OTHER